BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/14/2015 12:06:00 PM | Browse: 1034 | Download: 1780
 |
Received |
|
2015-04-22 09:23 |
 |
Peer-Review Started |
|
2015-04-22 19:35 |
 |
To Make the First Decision |
|
2015-06-19 17:37 |
 |
Return for Revision |
|
2015-06-24 16:31 |
 |
Revised |
|
2015-07-02 18:27 |
 |
Second Decision |
|
2015-08-10 08:19 |
 |
Accepted by Journal Editor-in-Chief |
|
2015-08-11 15:45 |
 |
Accepted by Executive Editor-in-Chief |
|
2015-08-31 17:26 |
 |
Articles in Press |
|
2015-08-31 17:26 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2015-09-19 00:39 |
 |
Typeset the Manuscript |
|
2015-09-24 10:11 |
 |
Publish the Manuscript Online |
|
2015-10-14 12:06 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Basic Study |
Article Title |
Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Yu-Lin Sun, Jian-Qiang Cai, Fang Liu, Xin-Yu Bi, Lan-Ping Zhou and Xiao-Hang Zhao |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
State Key Project for Infectious Diseases |
2013ZX10002009 |
State Key Project for Infectious Diseases |
2012ZX10002-017 |
National Basic Research Program of China |
2014CBA02001 |
National Basic Research Program of China |
2014CBA02002 |
National High-tech R&D Program of China |
2012AA020206 |
National Natural Science Foundation of China |
81071789 |
National Natural Science Foundation of China |
81321091 |
|
Corresponding Author |
Xiao-Hang Zhao, MD, PhD, Professor, State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli 17, Chaoyang District, Beijing 100021, China. zhaoxh@cicams.ac.cn |
Key Words |
Peroxiredoxin 1; Liver cancer; Prognostic factor; Post-translational modification; SUMOylation |
Core Tip |
Peroxiredoxin 1 (PRDX1) is an antioxidant enzyme, and, therefore, it is considered a tumor suppressor gene. However, only recently has various data revealed that PRDX1 not only functions in peroxide detoxification but also in tumorigenesis. Here, we found that PRDX1 was overexpressed in liver cancer at the transcriptional level, and it was an independent unfavorable prognostic factor for overall survival. In liver cancer cells, PRDX1 is post-translationally modified by small ubiquitin-like modifier. The downregulation of sumoylated PRDX1 in tumors might participate in hepatocarcinogenesis. PRDX1 represents both a prognostic biomarker and therapeutic target for liver cancer. |
Publish Date |
2015-10-14 12:06 |
Citation |
Sun YL, Cai JQ, Liu F, Bi XY, Zhou LP, Zhao XH. Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer. World J Gastroenterol 2015; 21(38): 10840-10852 |
URL |
http://www.wjgnet.com/1007-9327/full/v21/i38/10840.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v21.i38.10840 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345